Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 12, 34
eCollection

Patient Engagement and Patient Support Programs in Allergy Immunotherapy: A Call to Action for Improving Long-Term Adherence

Affiliations
Review

Patient Engagement and Patient Support Programs in Allergy Immunotherapy: A Call to Action for Improving Long-Term Adherence

Pascal Demoly et al. Allergy Asthma Clin Immunol.

Abstract

Allergy immunotherapy (AIT) is acknowledged to produce beneficial mid- and long-term clinical and immunologic effects and increased quality of life in patients with allergic respiratory diseases (such as allergic rhinoconjunctivitis and allergic asthma). However, poor adherence to AIT (due to intentional and/or non-intentional factors) is still a barrier to achieving these benefits. There is an urgent need for patient support programs (PSPs) that encompass communication, educational and motivational components. In the field of AIT, a PSP should be capable of (1) improving adherence, (2) boosting patient engagement, (3) explaining how AIT differs from pharmacological allergy treatments; (4) increasing health literacy about chronic, progressive, immunoglobulin-E-mediated immune diseases, (5) helping the patient to understand and manage local or systemic adverse events, and (6) providing and/or predicting local data on aeroallergen levels. We reviewed the literature in this field and have identified a number of practical issues to be addressed when implementing a PSP for AIT: the measurement of adherence, the choice of technologies, reminders, communication channels and content, the use of "push" messaging and social networks, interactivity, and the involvement of caregivers and patient leaders. A key issue is "hi-tech" (i.e. approaches based mainly on information technology) vs. "hi-touch" (based mainly on interaction with humans, i.e. family members, patient mentors and healthcare professionals). We conclude that multistakeholder PSPs (combining patient-, provider and society-based actions) must now be developed and tested with a view to increasing adherence, efficacy and safety in the field of AIT.

Keywords: Adherence; Allergy immunotherapy; Patient engagement; Patient support program.

Figures

Fig. 1
Fig. 1
A schematic diagram of the components of adherence. Adapted from [–8]

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

  • Clinical Trials in Allergen Immunotherapy: Current Concepts and Future Needs
    O Pfaar et al. Allergy 73 (9), 1775-1783. PMID 29446469. - Review
    Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested-primar …
  • [Adherence in Specific Immunotherapy]
    ML Lemberg et al. Hautarzt 68 (4), 282-286. PMID 28213675. - Review
    Allergies are steadily gaining in importance in the Western world. For over one hundred years, immunology has been the only causal treatment. Specific immunotherapy (SIT) …

References

    1. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–1296. doi: 10.1016/j.jaci.2013.01.049. - DOI - PubMed
    1. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11:586–593. doi: 10.1097/ACI.0b013e32834cb994. - DOI - PubMed
    1. Demoly P, Calderon MA, Casale TB, Malling HJ, Wahn U. The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis. Clin Transl Allergy. 2015;5:18. doi: 10.1186/s13601-015-0061-z. - DOI - PMC - PubMed
    1. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–568. doi: 10.1016/j.jaci.2015.04.047. - DOI - PubMed
    1. Committee for Medicinal Products for Human Use at the European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases, Draft CHMP/EWP/18504/2006. London: 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf. Accessed 6 Jan 2016.

LinkOut - more resources

Feedback